

VETOQUINOL PUBLISHES ITS REGISTRATION DOCUMENT AND ITS ANNUAL FINANCIAL REPORT RELATIVE TO FISCAL YEAR 2016 (FRENCH VERSION)

The **registration document** of Vetoquinol relative to fiscal year 2016, including the **annual financial report** relative to fiscal year 2016, was filed with the *Autorité des marchés financiers* (“the AMF”) on April 26, 2017.

It can be read or downloaded on the websites of:

- Vetoquinol (www.vetoquinol.com)
- AMF (www.amf-france.org)

It is also available to the public free of charge upon simple request:

- by mail: **Vetoquinol**
Communication financière
Magny-Vernois - BP 189 - 70204 Lure Cedex - France
- by e-mail: relations.investisseurs@vetoquinol.com
- by phone: +33 (0)3 84 62 59 88

The registration document integrates among other:

- the report of the President of the Board of directors on the corporate governance and on the internal control established upon provisions of article L. 225-37 of the French Commercial code;
- the management report;
- the sustainable development report;
- the statutory auditors' reports;
- the information relative to the fees paid to the statutory auditors.

Next update: First half 2017 results, July 27, 2017 after market close

About Vetoquinol

Vetoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia/Pacific region.

Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employs 2,084 people.

Vetoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For further information, go to: www.vetoquinol.com.

For more information, contact:

VETOQUINOL

Investor Relations

Marie-Josée Aubry-Rota

Tel.: +33 (0)3 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor and Media Relations

Emmanuel Dovergne

Tel.: +33 (0)1 56 43 44 63

emmanuel.dovergne@keima.fr